These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39414593)

  • 1. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）].
    Chinese Multidisciplinary Expert Consensus on the Rational Use of Surufatinib in Clinical Practice-Editorial Board Group
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):930-939. PubMed ID: 39414593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
    Lu X; Yan S; Koral KA; Chen Z
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
    [No Abstract]   [Full Text] [Related]  

  • 3. Surufatinib: First Approval.
    Syed YY
    Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
    Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
    Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
    Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
    Xu J
    Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
    Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
    Strosberg JR; Fisher GA; Benson AB; Anthony LB; Arslan B; Gibbs JF; Greeno E; Iyer RV; Kim MK; Maples WJ; Philip PA; Wolin EM; Cherepanov D; Broder MS
    World J Gastroenterol; 2015 Feb; 21(8):2450-9. PubMed ID: 25741154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surufatinib in neuroendocrine tumours.
    Das M
    Lancet Oncol; 2019 Apr; 20(4):e196. PubMed ID: 30880071
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Pelle' E; Strosberg J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
    Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
    J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.
    Agarwal P; Mohamed A
    Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
    Castellano D; Grande E; Valle J; Capdevila J; Reidy-Lagunes D; O'Connor JM; Raymond E
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1099-114. PubMed ID: 25480314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.